Therapeutic Clinical Investigation Consortium ("Therapy Consortium")

To ensure that leading cancer centers maintain a robust infrastructure for conducting prostate cancer clinical trials, the Prostate Cancer Foundation has provided more than $25 million to eight leading prostate cancer programs and formed the Therapy Consortium.  These institutions have agreed to work in a collaborative manner to rapidly and efficiently develop promising prostate cancer therapies.

The clinical investigators that comprise the Therapy Consortium are among the most respected prostate cancer researchers in the United States. The existence of the consortium is a powerful motivator for the pharmaceutical industry to develop prostate cancer drugs, since it is available to help quickly advance clinical development of promising investigational compounds. The consortium has also provided scientific guidance on clinical trial design to the pharmaceutical industry, helping to reduce the time needed to move a drug candidate from discovery to clinical development.
 
Current members of the Consortium include:                                                                                                 
• Cedars-Sinai Medical Center, Louis Warschaw Prostate Cancer Center (Los Angeles, CA): David B. Agus, M.D., Research Director

• Dana-Farber Cancer Institute (Boston, MA): Philip Kantoff, M.D.,  Director, The Lank Center for Genitourinary Oncology and Chief, Division of Solid Tumor Oncology

• The Johns Hopkins University, Sidney Kimmel Cancer Center (Baltimore, MD): Mario A. Eisenberger, M.D., R. Dale Hughes Professorship in Oncology and Professor of Urology; Michael A. Carducci, M.D., Associate Professor of Oncology and Urology and Co-Director, Drug Development Program; and William G. Nelson, M.D., Ph.D., Professor of Oncology, Urology, Pharmacology, Medicine, Pathology and Radiation Oncology, Director, Molecular Pharmacology Laboratory, Co-Director, Anti-Cancer Drug Discovery and Development Program, and Co-Director, Genitourinary Oncology Program

• M.D. Anderson Cancer Center, University of Texas (Houston, TX): Christopher J. Logothetis, M.D., Chair and Professor, Genitourinary Medical Oncology

• Memorial Sloan-Kettering Cancer Center (New York, NY): Howard I. Scher, M.D., Chief, Genitourinary Oncology Service and D. Wayne Calloway Chair in Urologic Oncology

• University of California, San Francisco Comprehensive Cancer Center (San Francisco, CA): Eric J. Small, M.D., Professor of Medicine and Urology

• University of Michigan Medical Center (Ann Arbor, MI): Kenneth J. Pienta, M.D., Professor of Medicine and Surgery and the University of Michigan Comprehensive Cancer Center: Maha Hussain, M.D.

• University of Wisconsin Comprehensive Cancer Center (Madison, WI): George Wilding, M.D., Director